Form 4 for PMCB PharmaCyte Biotech, Inc.
Accepted 2025-12-12 00:00:00 ET · period of report 2025-12-12 · accession 0001683168-25-009114 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-12 | 2025-12-12 | PMCB | Silverman Joshua | CEO, Pres, Dir | A - Grant | $0.00 | +575.0K | 575.0K | New | $0 | |
| 2025-12-12 | 2025-12-12 | PMCB | Silverman Joshua | CEO, Pres, Dir | F - Tax | $1.02 | -258.8K | 316.2K | -45% | -$263.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-12 | A | A | 575,000 | $0.00 | 575,000 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-12 | F | D | 258,750 | $1.02 | 316,250 | D | — | — | (F1) Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. |